annual EBITDA:
$20.71B+$2.46B(+13.48%)Summary
- As of today (April 17, 2025), NVS annual EBITDA is $20.71 billion, with the most recent change of +$2.46 billion (+13.48%) on December 31, 2024.
- During the last 3 years, NVS annual EBITDA has fallen by -$10.20 billion (-32.99%).
- NVS annual EBITDA is now -32.99% below its all-time high of $30.91 billion, reached on December 31, 2021.
Performance
NVS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$5.19B-$426.00M(-7.59%)Summary
- As of today (April 17, 2025), NVS quarterly EBITDA is $5.19 billion, with the most recent change of -$426.00 million (-7.59%) on December 31, 2024.
- Over the past year, NVS quarterly EBITDA has dropped by -$61.00 million (-1.16%).
- NVS quarterly EBITDA is now -68.61% below its all-time high of $16.53 billion, reached on December 31, 2021.
Performance
NVS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$20.71B+$1.01B(+5.10%)Summary
- As of today (April 17, 2025), NVS TTM EBITDA is $20.71 billion, with the most recent change of +$1.01 billion (+5.10%) on December 31, 2024.
- Over the past year, NVS TTM EBITDA has increased by +$1.74 billion (+9.14%).
- NVS TTM EBITDA is now -32.99% below its all-time high of $30.91 billion, reached on December 31, 2021.
Performance
NVS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NVS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.5% | -1.2% | +9.1% |
| 3 y3 years | -33.0% | +39.9% | -27.5% |
| 5 y5 years | +32.6% | +23.2% | +26.3% |
NVS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -33.0% | +41.1% | -7.6% | +44.2% | -32.8% | +32.6% |
| 5 y | 5-year | -33.0% | +41.1% | -68.6% | +44.2% | -33.0% | +32.6% |
| alltime | all time | -33.0% | +272.7% | -68.6% | +147.2% | -33.0% | +1480.1% |
Novartis AG EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $20.71B(+13.5%) | $5.19B(-7.6%) | $20.71B(+5.1%) |
| Sep 2024 | - | $5.61B(+7.0%) | $19.71B(+3.8%) |
| Jun 2024 | - | $5.25B(+12.5%) | $18.98B(+3.6%) |
| Mar 2024 | - | $4.66B(+11.5%) | $18.33B(+0.4%) |
| Dec 2023 | $18.25B(+24.3%) | $4.18B(-14.4%) | $18.25B(+3.3%) |
| Sep 2023 | - | $4.88B(+6.2%) | $17.67B(+7.1%) |
| Jun 2023 | - | $4.60B(+0.2%) | $16.49B(+3.5%) |
| Mar 2023 | - | $4.59B(+27.6%) | $15.94B(+2.0%) |
| Dec 2022 | $14.68B(-52.5%) | $3.60B(-3.0%) | $15.63B(-45.3%) |
| Sep 2022 | - | $3.71B(-8.4%) | $28.56B(-4.0%) |
| Jun 2022 | - | $4.05B(-5.4%) | $29.73B(-3.6%) |
| Mar 2022 | - | $4.28B(-74.1%) | $30.84B(-0.2%) |
| Dec 2021 | $30.91B(+79.6%) | $16.53B(+238.4%) | $30.91B(+64.8%) |
| Sep 2021 | - | $4.88B(-5.2%) | $18.76B(+2.9%) |
| Jun 2021 | - | $5.15B(+18.4%) | $18.23B(+5.4%) |
| Mar 2021 | - | $4.35B(-0.6%) | $17.29B(+0.5%) |
| Dec 2020 | $17.21B(+10.2%) | $4.38B(+0.6%) | $17.21B(+2.9%) |
| Sep 2020 | - | $4.35B(+3.4%) | $16.73B(+2.0%) |
| Jun 2020 | - | $4.21B(-1.4%) | $16.41B(+2.0%) |
| Mar 2020 | - | $4.27B(+9.5%) | $16.08B(+3.0%) |
| Dec 2019 | $15.62B(-22.8%) | $3.90B(-3.1%) | $15.62B(+4.6%) |
| Sep 2019 | - | $4.03B(+3.6%) | $14.93B(+1.2%) |
| Jun 2019 | - | $3.88B(+2.0%) | $14.75B(-28.0%) |
| Mar 2019 | - | $3.81B(+18.3%) | $20.48B(+1.2%) |
| Dec 2018 | $20.24B(+38.7%) | $3.22B(-16.3%) | $20.24B(+2.2%) |
| Sep 2018 | - | $3.85B(-60.0%) | $19.81B(-1.3%) |
| Jun 2018 | - | $9.61B(+169.8%) | $20.07B(+54.8%) |
| Mar 2018 | - | $3.56B(+27.8%) | $12.97B(+12.5%) |
| Dec 2017 | $14.59B(+0.1%) | $2.79B(-32.2%) | $11.53B(-1.4%) |
| Sep 2017 | - | $4.11B(+64.0%) | $11.69B(+1.3%) |
| Jun 2017 | - | $2.51B(+17.9%) | $11.54B(-9.8%) |
| Mar 2017 | - | $2.13B(-27.8%) | $12.79B(-12.2%) |
| Dec 2016 | $14.57B(+2.2%) | $2.95B(-25.5%) | $14.57B(+2.3%) |
| Sep 2016 | - | $3.96B(+5.2%) | $14.23B(+2.0%) |
| Jun 2016 | - | $3.76B(-3.8%) | $13.96B(-0.5%) |
| Mar 2016 | - | $3.91B(+49.4%) | $14.03B(-1.6%) |
| Dec 2015 | $14.26B(-19.2%) | $2.61B(-28.9%) | $14.26B(-9.8%) |
| Sep 2015 | - | $3.68B(-3.9%) | $15.81B(-7.1%) |
| Jun 2015 | - | $3.83B(-7.5%) | $17.02B(-3.7%) |
| Mar 2015 | - | $4.14B(-0.6%) | $17.67B(+0.1%) |
| Dec 2014 | $17.66B(+11.1%) | $4.17B(-14.6%) | $17.66B(+3.3%) |
| Sep 2014 | - | $4.88B(+8.8%) | $17.09B(+7.1%) |
| Jun 2014 | - | $4.49B(+8.9%) | $15.97B(+1.0%) |
| Mar 2014 | - | $4.12B(+14.5%) | $15.80B(-0.5%) |
| Dec 2013 | $15.89B(-3.1%) | $3.60B(-4.1%) | $15.89B(-0.8%) |
| Sep 2013 | - | $3.75B(-13.2%) | $16.02B(-2.6%) |
| Jun 2013 | - | $4.33B(+2.8%) | $16.46B(-1.1%) |
| Mar 2013 | - | $4.21B(+12.8%) | $16.64B(+1.5%) |
| Dec 2012 | $16.40B | $3.73B(-11.0%) | $16.40B(+4.7%) |
| Sep 2012 | - | $4.19B(-7.1%) | $15.66B(-2.1%) |
| Jun 2012 | - | $4.51B(+13.7%) | $16.00B(-1.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $3.97B(+32.7%) | $16.31B(-4.6%) |
| Dec 2011 | $17.09B(+8.1%) | $2.99B(-34.1%) | $17.09B(-2.2%) |
| Sep 2011 | - | $4.53B(-5.9%) | $17.48B(+1.8%) |
| Jun 2011 | - | $4.82B(+1.4%) | $17.16B(+6.3%) |
| Mar 2011 | - | $4.75B(+40.9%) | $16.14B(+2.1%) |
| Dec 2010 | $15.81B(+23.8%) | $3.37B(-20.1%) | $15.81B(-0.4%) |
| Sep 2010 | - | $4.22B(+11.1%) | $15.88B(+6.3%) |
| Jun 2010 | - | $3.80B(-14.2%) | $14.94B(+4.7%) |
| Mar 2010 | - | $4.42B(+28.7%) | $14.27B(+11.7%) |
| Dec 2009 | $12.77B(+2.5%) | $3.44B(+4.9%) | $12.77B(+9.0%) |
| Sep 2009 | - | $3.28B(+4.8%) | $11.72B(-0.8%) |
| Jun 2009 | - | $3.13B(+6.8%) | $11.82B(-1.3%) |
| Mar 2009 | - | $2.93B(+22.8%) | $11.98B(-1.6%) |
| Dec 2008 | $12.46B(+17.7%) | $2.39B(-29.3%) | $12.17B(+3.0%) |
| Sep 2008 | - | $3.38B(+2.7%) | $11.82B(+3.3%) |
| Jun 2008 | - | $3.29B(+5.3%) | $11.44B(+6.2%) |
| Mar 2008 | - | $3.12B(+53.4%) | $10.78B(+2.3%) |
| Dec 2007 | $10.58B(+3.9%) | $2.04B(-32.1%) | $10.53B(-7.3%) |
| Sep 2007 | - | $3.00B(+14.1%) | $11.36B(+4.2%) |
| Jun 2007 | - | $2.63B(-8.7%) | $10.91B(+1.4%) |
| Mar 2007 | - | $2.88B(+0.3%) | $10.76B(+3.8%) |
| Dec 2006 | $10.18B(+16.0%) | $2.87B(+12.8%) | $10.37B(+5.9%) |
| Sep 2006 | - | $2.54B(+2.8%) | $9.79B(+1.6%) |
| Jun 2006 | - | $2.47B(-0.5%) | $9.63B(+3.5%) |
| Mar 2006 | - | $2.49B(+8.7%) | $9.30B(+5.9%) |
| Dec 2005 | $8.78B(+10.2%) | $2.29B(-4.1%) | $8.78B(+3.3%) |
| Sep 2005 | - | $2.39B(+11.3%) | $8.50B(+4.2%) |
| Jun 2005 | - | $2.14B(+9.1%) | $8.16B(+0.4%) |
| Mar 2005 | - | $1.97B(-2.2%) | $8.13B(+2.0%) |
| Dec 2004 | $7.97B(+9.8%) | $2.01B(-1.8%) | $7.97B(-0.2%) |
| Sep 2004 | - | $2.05B(-3.0%) | $7.98B(+2.8%) |
| Jun 2004 | - | $2.11B(+17.0%) | $7.77B(+4.8%) |
| Mar 2004 | - | $1.80B(-10.9%) | $7.41B(+2.0%) |
| Dec 2003 | $7.26B(+1.0%) | $2.02B(+10.5%) | $7.26B(-8.1%) |
| Sep 2003 | - | $1.83B(+4.5%) | $7.90B(+4.6%) |
| Jun 2003 | - | $1.75B(+5.9%) | $7.56B(+4.3%) |
| Mar 2003 | - | $1.66B(-37.9%) | $7.25B(-30.6%) |
| Dec 2002 | $7.19B(+20.9%) | $2.67B(+79.5%) | $10.45B(-796.4%) |
| Sep 2002 | - | $1.49B(+3.1%) | -$1.50B(-158.0%) |
| Jun 2002 | - | $1.44B(-70.3%) | $2.59B(+22.2%) |
| Mar 2002 | - | $4.86B(-152.3%) | $2.12B(+24.6%) |
| Dec 2001 | $5.95B(+5.7%) | -$9.29B(-266.6%) | $1.70B(>+9900.0%) |
| Sep 2001 | - | $5.58B(+474.3%) | $0.00(-100.0%) |
| Jun 2001 | - | $971.00M(-78.1%) | -$695.00M(+4.4%) |
| Mar 2001 | - | $4.44B(-140.4%) | -$666.00M(-212.7%) |
| Dec 2000 | $5.63B(+1.2%) | -$10.99B(-325.1%) | $591.00M(-94.9%) |
| Sep 2000 | - | $4.88B(+388.1%) | $11.58B(+72.9%) |
| Jun 2000 | - | $1.00B(-82.4%) | $6.70B(+17.6%) |
| Mar 2000 | - | $5.70B | $5.70B |
| Dec 1999 | $5.56B(-7.9%) | - | - |
| Dec 1998 | $6.04B | - | - |
FAQ
- What is Novartis AG annual EBITDA?
- What is the all time high annual EBITDA for Novartis AG?
- What is Novartis AG annual EBITDA year-on-year change?
- What is Novartis AG quarterly EBITDA?
- What is the all time high quarterly EBITDA for Novartis AG?
- What is Novartis AG quarterly EBITDA year-on-year change?
- What is Novartis AG TTM EBITDA?
- What is the all time high TTM EBITDA for Novartis AG?
- What is Novartis AG TTM EBITDA year-on-year change?
What is Novartis AG annual EBITDA?
The current annual EBITDA of NVS is $20.71B
What is the all time high annual EBITDA for Novartis AG?
Novartis AG all-time high annual EBITDA is $30.91B
What is Novartis AG annual EBITDA year-on-year change?
Over the past year, NVS annual EBITDA has changed by +$2.46B (+13.48%)
What is Novartis AG quarterly EBITDA?
The current quarterly EBITDA of NVS is $5.19B
What is the all time high quarterly EBITDA for Novartis AG?
Novartis AG all-time high quarterly EBITDA is $16.53B
What is Novartis AG quarterly EBITDA year-on-year change?
Over the past year, NVS quarterly EBITDA has changed by -$61.00M (-1.16%)
What is Novartis AG TTM EBITDA?
The current TTM EBITDA of NVS is $20.71B
What is the all time high TTM EBITDA for Novartis AG?
Novartis AG all-time high TTM EBITDA is $30.91B
What is Novartis AG TTM EBITDA year-on-year change?
Over the past year, NVS TTM EBITDA has changed by +$1.74B (+9.14%)